Patents Assigned to EMMUNE, INC.
  • ACE2 muteins and methods of using the same
    Patent number: 12674153
    Abstract: The invention relates generally to non-naturally occurring ACE2 proteins and their use in the treatment of coronavirus infection.
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: July 7, 2026
    Assignee: Emmune, Inc.
    Inventors: Charles C. Bailey, Michael D. Alpert
  • CD4 muteins and methods of using the same
    Patent number: 12252527
    Abstract: The invention relates to proteins that contain the CD4 domain 1 and the CD4 domain 2 (CD4 D1D2), wherein the CD4 D1D2 contains one or more mutations compared to wild-type human CD4 D1D2, and to methods of using the proteins for treating a human immunodeficiency virus (HIV) infection in a subject.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: March 18, 2025
    Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, EMMUNE, INC.
    Inventors: Michael Farzan, Matthew Gardner, Ina Fetzer, Michael Alpert, Charles Bailey